On Windows systems, you can press ALT + an access key. On Macintosh, you can press Control + an access key.

About Us /
Board of Directors

Peter Tuxen Bisgaard, Novo Ventures

Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2009, and Boston, Massachusetts from 2015. He is chairman of the Board of Directors of HTG Molecular Diagnostics Inc. (NASDAQ:HTG) and Otonomy Inc., (NASDAQ:OTIC) and a member of the Board of Directors of Ceterix Orthopaedics Inc. Previously, he was among other companies board member of Nevro (NASDAQ: NVRO) and Alder (NASDAQ:ALDR). From 2001-2009, Peter was employed with Novo A/S as a partner in Novo Ventures. Prior to joining Novo A/S he was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. At McKinsey, Peter focused on strategy development, mergers, acquisitions and alliances in various industries. Peter is the co-author of 'Growth by Mergers & Acquisitions' published by Børsens Forlag, 2004. Peter obtained an MSc in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.

Markus Goebel, Novartis Venture Fund

Markus Goebel started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters to include a worldwide alliance with Amgen. He joined Novartis in 2000 and first worked as Global Head Nervous System BD&L Pharma and later as Global Head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US, moving back to Europe in 2009. Previously he received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen, Intellikine and LigoCyte.

Jason Lettman, Morgenthaler Ventures

Jason Lettman is a Partner of Morgenthaler Ventures and a Partner of Lightstone Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. He currently represents Morgenthaler on the boards of Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, Spinewave and Vapotherm and represents Lightstone on the board of FIRE1. Prior to Lightstone, Jason was a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. Jason was also a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014). Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe.

Before joining Morgenthaler, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical, EBR Systems, Evalve (acquired by Abbott Labs), Miramar Labs as well as with the founding of Zyga Technologies.

Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group, which focused on corporate venture and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.

Jason has an MBA with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.

Ed Mathers, New Enterprise Associates

Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO). Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Rajeev Shah, RA Capital Management

Rajeev Shah is a Managing Director and Portfolio Manager at RA Capital Management. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Raj is active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms, Prior to joining RA Capital, Raj worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals. At Altus, he assessed business processes and implemented system solutions for all science areas. Raj graduated from Cornell University, where he majored in Chemistry with a concentration in Economics.

Doug Treco, Ra Pharmaceuticals

Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his PhD in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.